

# Anti-Thrombin III



800.948.9834 ■ [www.bdipharma.com](http://www.bdipharma.com)

PRODUCT SPECIFICS	Thrombate-III®	ATryn®
INDICATIONS	Treatment of patients with hereditary antithrombin III deficiency in connection with surgical or obstetrical procedures or when they suffer from thromboembolism	Prevention of peri-operative and peri-partum thromboembolic events in hereditary antithrombin deficient patients
CONTRAINDICATIONS	None known	Contraindicated in patients with known hypersensitivity to goat and goat milk proteins
SOURCE OF ANTITHROMBIN	Plasma-derived. Thrombate III® is made from large pools of human plasma donated at centers within the US	Recombinant human antithrombin produced through recombinant DNA technology using genetically engineered goats. DNA sequence directs the antithrombin expression into goat's milk.
VIRAL SAFETY PROCESS	Heat treatment in solution at 60°C for no less than 10 hours	Tangential Flow Filtration, Affinity Chromatography, Nanofiltration, Ion Exchange Chromatography, Hydrophobic Interaction Chromatography, Heat Treatment. Log10 reductions range from ≥ 13.2 log to ≥ 20.0 log.
ROUTE OF ADMINISTRATION	Bolus intravenous infusion (over 10-20 minutes)	May be administered intravenously via sterile syringe or via an infusion bag
PRODUCT HALF LIFE	3.8 days	11.6 - 17.7 hours
SHELF LIFE FROM DATE OF MANUFACTURE	36 months. Do not use after the labeled expiration date	4 years
SHELF LIFE AFTER RECONSTITUTION	3 hours	8 -12 hours
STORAGE REQUIREMENTS	Store at room temperature not to exceed 25°C (77°F). Freezing should be avoided as breakage of the diluent bottle might occur	Store refrigerated between 2°-8° C (36°-46° F)
DILUENT VOLUME	10mL	10mL
AVAILABLE VIAL SIZES	500 IU vials with sterile water for injection, filter, and transfer needles	Approximately 1750 IU (exact potency stated on label), 20 mL vial size

IMPORTANT NOTICE - The information provided herein is a summary of available information only. This summary is to be used as a general educational tool and is not intended for use as a guideline for clinical evaluations. Such evaluations (including but not limited to initial and/or subsequent dosing, conversions from specific product brands, etc.) should utilize a thorough review of appropriate clinical data. For a copy of a product insert or to request any additional information at our disposal, please contact us at 1-800-948-9834. The possibility of error (typographical or otherwise) exists in this summary. No liability is assumed by the distributor for improper use of this literature. ©2011. BDI Pharma, Inc. All rights reserved.